Company's Previous Response Left Unanswered Questions About EpiPen Pricing Impact on Consumers, Taxpayers, and Insurance Premiums

PEORIA – U.S. Senator Dick Durbin (D-IL) today joined a group of 17 senators requesting additional information from the CEO of pharmaceutical company Mylan about the recent EpiPen Auto-Injector (EpiPen) price increases and how Mylan's pricing strategy affects consumers, taxpayers, and insurance premiums. The letter follows a previous request for information made in August about the EpiPen price hike. Today’s letter was also signed by Senators Elizabeth Warren (D-MA), Tammy Baldwin (D-WI), Richard Blumenthal (D-CT), Barbara Boxer (D-CA), Sherrod Brown (D-OH), Al Franken (D-MN), Kirsten Gillibrand (D-NY), Mazie K. Hirono (D-HI), Amy Klobuchar (D-MN), Patrick Leahy (D-VT), Edward J. Markey (D-MA), Chris Murphy (D-CT), Jack Reed (D-RI), Bernie Sanders (I-VT), Tom Udall (D-NM), and Sheldon Whitehouse (D-RI).

Get The Latest News!

Don't miss our top stories and need-to-know news everyday in your inbox.

Article continues after sponsor message

Mylan's response to the August letter revealed that:

  • Mylan's My EpiPen Savings Card and Patient Assistance Program do not help the vast majority of EpiPen users – in fact, the free product provided through the Patient Assistance Program touted by Mylan represents less than 1% of all EpiPens sold.
  • The majority of EpiPen's cost increases appear to have been borne by taxpayers, via higher costs for programs like Medicare and Medicaid, and by employers and insured patients, via higher premiums.
  • Mylan's pricing system is complex and non-transparent, allowing the company to segregate consumers into different categories, charging different prices to different customers while shielding some customers from price increases and shifting costs to others.

Mylan, however, failed to provide important information needed to put these findings in context. The senators explained in today's letter to Mylan that they "remain frustrated with both the lack of information and lack of clarity in your response, and your insistence that you are not aware of basic facts about sales of your own drug to Medicaid and Medicare Part D."

The letter seeks additional information on Mylan's pricing strategy, particularly after Mylan provided information revealing a significant gap between the listed Wholesale Acquisition Cost for EpiPen and what consumers actually pay, and that the company is manipulating prices in order to maximize its revenue.

"Mylan appears to be engaging in practices that shield some consumers from price increases and high deductibles while shifting these costs-both directly and indirectly-to others. The net result of this process is profitable for Mylan-but these increased revenues come at a significant cost to consumers and taxpayers," wrote the senators.  

Article continues after sponsor message

The letter requests that Mylan provide answers to a series of questions about its pricing strategies for four different groups of customers – the uninsured, Medicated patients, Medicare patients, and patients with employer or Affordable Care Act insurance coverage – and how the company's approach to pricing affects its revenue and patient access to the EpiPen.

Prefer RiverBender on Google
Your community. Your stories. From school milestones to decisions at city hall, local stories deserve coverage. Subscribe to help RiverBender keep telling them.
Support Local Journalism
Copyright 2026 Riverbender.com. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

 

More like this:

Budzinski Applauds $63 Million Family Dollar Settlement, Calls For End To Deceptive Pricing Practices
5 days ago
Budzinski Leads 33 Lawmakers In Demanding FTC Investigation Into Overcharging By Dollar, Convenience Stores
Oct 30, 2026
Family Dollar to Pay $63 Million in National Price-Transparency Settlement
5 days ago
Attorney General Raoul Files Lawsuit Against Dollar General For Charging Consumers More Than Advertised Price For Many Products
Oct 26, 2026
Giannoulias Insurance Reform Delivers Historic Consumer Protections for Illinois Drivers
Aug 4, 2026